The U.S. stock market kicked off 2026 with a volatile start, but by the end of February, the S&P 500 had clawed back its losses to close within just 1.8% of its all-time high. Looking back, 2025 was a strong year, with the index gaining more than 16%—marking its third consecutive year of above-average returns. As the new year unfolds, investors are hopeful that this positive momentum can continue.
Amidst sector rotation, several companies with unique catalysts have emerged as standout performers. So far this year, biotech firms with significant clinical breakthroughs, along with select semiconductor and AI infrastructure stocks, have delivered the most impressive gains. Here are the six top-performing stocks of 2026 among companies traded on major U.S. exchanges with market caps of at least $1 billion.
ImmunityBio is a biotechnology company focused on developing therapies and vaccines for cancer and infectious diseases. Its lead drug, Anktiva, works by enhancing and leveraging the body’s natural immune system to fight disease. The company is currently testing Anktiva in combination with other drugs to treat various conditions, including cancer and Lynch syndrome.
Since the start of 2026, ImmunityBio has commercially launched Anktiva in Saudi Arabia and established an Irish subsidiary to prepare for a European launch. Additionally, the company reported impressive efficacy and safety data from its non-Hodgkin lymphoma clinical study. This series of positive developments has ignited investor enthusiasm, sending IBRX shares up an astounding 393.9% year-to-date.
Erasca is a clinical-stage biotechnology company singularly focused on targeting cancers driven by the RAS/MAPK pathway, including colorectal cancer, non-small cell lung cancer, and melanoma. Its pipeline includes key assets like ERAS-0015, ERAS-4001, and ERAS-12, all designed to shut down this critical signaling pathway.
In January, Erasca reported positive clinical data for ERAS-0015, confirming partial responses in treating multiple tumor types with different RAS mutations. The treatment also showed encouraging safety and tolerability. While ERAS-0015 is still in Phase 1 testing, Erasca’s current $4.2 billion market capitalization makes it a potential acquisition target. These catalysts have propelled ERAS stock up 267.2% in 2026.
Alumis is a clinical-stage biotechnology company focused on developing oral, small-molecule therapies for immune-mediated diseases. Its lead candidate, envudeucitinib (ESK-001), is being developed for moderate-to-severe plaque psoriasis and systemic lupus erythematosus.
In early January, Alumis announced that envudeucitinib achieved all primary and secondary endpoints in a Phase 3 clinical trial for patients with moderate-to-severe plaque psoriasis. The company also stated its plans to submit a New Drug Application to the FDA in the second half of 2026. Investors are betting on potential regulatory approval and a subsequent commercial launch, driving ALMS shares up 204.2% in the first two months of 2026.
SanDisk is one of the world’s largest suppliers of NAND flash memory semiconductors. The company operates a vertically integrated business, producing the vast majority of its flash chips at manufacturing sites across Japan. Since being spun off from Western Digital in February 2025, the stock has surged over 1,000%.
SanDisk has gained popularity as an AI play due to its manufacturing of storage devices used in AI data centers. Furthermore, supply shortages have led to surging NAND chip prices, significantly boosting the company’s profit margins. These tailwinds have driven SNDK stock up 167.6% so far in 2026.
Ichor Holdings designs and produces critical fluid delivery subsystems and components for leading semiconductor capital equipment manufacturers. Its core products include chemical dispensing systems, gas panels, and precision-machined components.
The company’s momentum accelerated in early February after it reported a significant fourth-quarter earnings beat and issued impressive growth guidance. Ichor’s management stated it anticipates “meaningfully improved gross margin” in fiscal 2026 as its profitability improvement strategies take shape. With analysts expecting healthy growth in wafer fabrication equipment spending this year, ICHR shares have gained 158% in 2026.
Kosmos Energy is a deepwater oil and gas exploration and production company with operations primarily in the U.S., Ghana, Mauritania, and Senegal. In February, Kosmos announced the sale of its production assets in Equatorial Guinea to Panoro Energy for $180 million, plus future contingent payments of up to $39.5 million.
This divestiture news came just days after Ghana’s parliament extended licenses for the Jubilee and TEN offshore fields through 2040. The extension includes up to $2 billion in incremental investments and 20 additional wells for Kosmos in the Jubilee field. These moves to optimize its portfolio and secure long-term growth have sent KOS shares up 156.7% year-to-date.
As this list demonstrates, the early leaders in the 2026 stock market are clustered in two main areas: biotechnology stocks experiencing explosive growth due to clinical breakthroughs or commercialization prospects, and semiconductor companies deeply integrated into the AI hardware infrastructure build-out. With the broader market hovering near all-time highs, stocks with strong, independent narratives have the potential to deliver returns that far outpace the indices. For investors, the ability to identify and capitalize on these unique catalysts could be a key determinant of their success this year.
